2,448 Shares in Quest Diagnostics Incorporated $DGX Purchased by Greenspring Advisors LLC

Greenspring Advisors LLC acquired a new position in Quest Diagnostics Incorporated (NYSE:DGX) in the second quarter, Holdings Channel reports. The fund acquired 2,448 shares of the medical research company’s stock, valued at approximately $519,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Davis Selected Advisers boosted its position in Quest Diagnostics by 16.8% in the fourth quarter. Davis Selected Advisers now owns 1,589,883 shares of the medical research company’s stock worth $275,895,000 after purchasing an additional 228,271 shares during the last quarter. ANTIPODES PARTNERS Ltd increased its position in shares of Quest Diagnostics by 178.7% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company’s stock valued at $29,847,000 after purchasing an additional 110,280 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Quest Diagnostics by 39.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 15,405 shares of the medical research company’s stock worth $3,265,000 after purchasing an additional 4,334 shares during the period. Advisors Capital Management LLC raised its stake in shares of Quest Diagnostics by 5.4% during the 4th quarter. Advisors Capital Management LLC now owns 313,838 shares of the medical research company’s stock worth $54,460,000 after purchasing an additional 16,194 shares during the period. Finally, International Assets Investment Management LLC purchased a new position in shares of Quest Diagnostics in the 4th quarter worth about $92,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Analyst Upgrades and Downgrades

DGX has been the subject of several research reports. Barclays increased their price target on shares of Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Argus set a $260.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research note on Tuesday, July 28th. UBS Group increased their target price on shares of Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Finally, Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Quest Diagnostics presently has an average rating of “Moderate Buy” and a consensus price target of $235.31.

Insider Transactions at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the sale, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the sale, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. The trade was a 13.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 19,747 shares of company stock worth $3,947,088 over the last quarter. Corporate insiders own 0.88% of the company’s stock.

Quest Diagnostics Stock Up 0.0%

Shares of NYSE DGX opened at $241.80 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. The stock has a market capitalization of $26.69 billion, a PE ratio of 25.67, a P/E/G ratio of 2.23 and a beta of 0.56. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $245.68. The business’s fifty day moving average price is $218.52 and its 200-day moving average price is $204.87.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The company had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the firm posted $2.62 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, equities research analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a $0.86 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.52%.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.